GC Biopharma (A006280) Stock Overview

A biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. More details

A006280 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	2/6
Financial Health	2/6
Dividends	1/6

Rewards

Trading at 8.6% below our estimate of its fair value

Became profitable this year

Analysts in good agreement that stock price will rise by 45.2%

Risk Analysis

Interest payments are not well covered by earnings

A006280 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

GC Biopharma Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for GC Biopharma
Historical stock prices
Current Share Price	₩133,900.00
52 Week High	₩180,300.00
52 Week Low	₩111,800.00
Beta	0.99
1 Month Change	2.45%
3 Month Change	2.53%
1 Year Change	-0.52%
3 Year Change	0.68%
5 Year Change	-62.18%
Change since IPO	-55.01%

Recent updates

Estimating The Intrinsic Value Of GC Biopharma Corp. (KRX:006280)

Nov 13

Insufficient Growth At GC Biopharma Corp. (KRX:006280) Hampers Share Price

Sep 23

Is GC Biopharma Corp. (KRX:006280) Trading At A 45% Discount?

Jul 03

GC Biopharma's (KRX:006280) Earnings May Just Be The Starting Point

May 23

Here's Why GC Biopharma (KRX:006280) Is Weighed Down By Its Debt Load

May 09

Is GC Biopharma Corp. (KRX:006280) Trading At A 39% Discount?

Mar 13

Benign Growth For GC Biopharma Corp. (KRX:006280) Underpins Stock's 25% Plummet

Nov 19

Does This Valuation Of GC Biopharma Corp. (KRX:006280) Imply Investors Are Overpaying?

Nov 07

Is GC Biopharma (KRX:006280) A Risky Investment?

Oct 17

There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

Aug 02

A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

Jul 12

Is GC Biopharma (KRX:006280) A Risky Investment?

May 25

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

May 02

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Mar 10

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Feb 18

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Jan 31

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

Jan 14

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Dec 27

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 09

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21

Shareholder Returns

	A006280	KR Biotechs	KR Market
7D	-3.9%	2.7%	-5.1%
1Y	-0.5%	47.4%	54.5%

Return vs Industry: A006280 underperformed the KR Biotechs industry which returned 47.4% over the past year.

Return vs Market: A006280 underperformed the KR Market which returned 54.5% over the past year.

Price Volatility

Is A006280's price volatile compared to industry and market?
A006280 volatility
A006280 Average Weekly Movement	3.8%
Biotechs Industry Average Movement	7.6%
Market Average Movement	5.2%
10% most volatile stocks in KR Market	10.8%
10% least volatile stocks in KR Market	2.5%

Stable Share Price: A006280 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A006280's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1967	2,042	Il-Sup Huh	www.gcbiopharma.com

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj.

GC Biopharma Corp. Fundamentals Summary

How do GC Biopharma's earnings and revenue compare to its market cap?
A006280 fundamental statistics
Market cap	₩1.53t
Earnings (TTM)	₩73.65b
Revenue (TTM)	₩1.79t

20.7x

P/E Ratio

0.9x

P/S Ratio

Is A006280 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A006280 income statement (TTM)
Revenue	₩1.79t
Cost of Revenue	₩1.26t
Gross Profit	₩533.55b
Other Expenses	₩459.90b
Earnings	₩73.65b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	6.45k
Gross Margin	29.81%
Net Profit Margin	4.12%
Debt/Equity Ratio	68.6%

How did A006280 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

23%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/20 02:37
End of Day Share Price	2025/11/20 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GC Biopharma Corp. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Lee	CLSA
Yoonjin Lim	Daishin Securities Co. Ltd.
Jun Yong Bang	Daiwa Securities Co. Ltd.

GC Biopharma (A006280) Stock Overview

Rewards

Risk Analysis

GC Biopharma Corp. Competitors

L&C BIOLTD

Medy-Tox

Green Cross Holdings

Hugel

Price History & Performance

Recent News & Updates

Estimating The Intrinsic Value Of GC Biopharma Corp. (KRX:006280)

GC Biopharma's Recombinant Anthrax Vaccine, Barythrax, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'

Insufficient Growth At GC Biopharma Corp. (KRX:006280) Hampers Share Price

GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea

GC Biopharma Submits IND to Begin Phase 3 Clinical Trial for BARYCELA in Thailand

GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal

Recent updates

Estimating The Intrinsic Value Of GC Biopharma Corp. (KRX:006280)

GC Biopharma's Recombinant Anthrax Vaccine, Barythrax, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'

Insufficient Growth At GC Biopharma Corp. (KRX:006280) Hampers Share Price

GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea

GC Biopharma Submits IND to Begin Phase 3 Clinical Trial for BARYCELA in Thailand

GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal

Second quarter 2025 earnings released: EPS: ₩3,329 (vs ₩608 loss in 2Q 2024)

Consensus EPS estimates increase by 82%

Consensus EPS estimates increase by 34%

GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam

Is GC Biopharma Corp. (KRX:006280) Trading At A 45% Discount?

GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting

GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal

GC Biopharma's (KRX:006280) Earnings May Just Be The Starting Point

Here's Why GC Biopharma (KRX:006280) Is Weighed Down By Its Debt Load

GC Biopharma Receives MFDS Approval for Recombinant Anthrax Vaccine

Full year 2024 earnings: EPS and revenues miss analyst expectations

Is GC Biopharma Corp. (KRX:006280) Trading At A 39% Discount?

New major risk - Dividend sustainability

GC Biopharma Corp., Annual General Meeting, Mar 26, 2025

Upcoming dividend of ₩1,500 per share

GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment

GC Biopharma USA Names Sean Zam as Head of Sales and Marketing

Benign Growth For GC Biopharma Corp. (KRX:006280) Underpins Stock's 25% Plummet

Does This Valuation Of GC Biopharma Corp. (KRX:006280) Imply Investors Are Overpaying?

Price target increased by 10% to ₩195,000

Now 21% overvalued after recent price rise

Is GC Biopharma (KRX:006280) A Risky Investment?

Price target increased by 11% to ₩188,333

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Price target increased by 7.7% to ₩162,000

There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

Now 21% overvalued after recent price rise

A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

New major risk - Financial position

Is GC Biopharma (KRX:006280) A Risky Investment?

Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Upcoming dividend of ₩1,750 per share at 1.4% yield

GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

Consensus EPS estimates fall from profit to ₩269 loss

GC Biopharma Applies for MFDS Approval

Consensus EPS estimates fall from profit to ₩1,046 loss

Consensus EPS estimates fall by 31%

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 18%, revenue downgraded

GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt

Consensus EPS estimates fall by 38%

Consensus EPS estimates increase by 11%

GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to ₩176,750

Upcoming dividend of ₩2,000 per share

Price target decreased to ₩191,222

Less than half of directors are independent

Now 21% undervalued after recent price drop

Price target decreased to ₩208,875

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased to ₩254,400

GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'

Investor sentiment improved over the past week